Levetiracetam Solution
Product Images NDC 53041-660

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53041-660). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Guardian Drug Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

660lev.jpg (660lev)

Label for Levetiracetam Oral Solution, USP, 100 mg/mL, provided by Guardian Drug Company. The label includes the NDC 53041-660-06, a warning to dispense a Medication Guide with each patient, and states the bottle size as 16 fl oz (473 mL). It also gives pharmacist storage instructions and the manufacturer's address in Dayton, New Jersey.*

FDA Label Image

Structure-1.jpg (Structure 1)

Chemical structure of levetiracetam depicting its molecular arrangement, including a pyrrolidone ring and associated functional groups, as shown in the image.*

FDA Label Image

Structure-3.jpg (Structure 3)

A bar graph comparing the percentage of patients among three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 3000 mg/day. The placebo group shows about 7.4% of patients, while the levetiracetam groups show higher percentages, 37.1% and 39.6% respectively, with statistical significance indicated versus placebo.*

FDA Label Image

Structure-4.jpg (Structure 4)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The percentages shown are 6.3% for Placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day. Statistical significance versus placebo is indicated.*

FDA Label Image

Structure-5.jpg (Structure 5)

A bar chart comparing the percentage of patients between two groups: placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The chart shows 14.4% of patients in the placebo group and 39.4% in the Levetiracetam group, with a notation indicating statistical significance versus placebo.*

FDA Label Image

Structure-6.jpg (Structure 6)

A bar chart comparing percentages of patients between placebo and Levetiracetam treatment groups. The chart shows approximately 19.6% of patients in the placebo group and 44.6% in the Levetiracetam group, with an asterisk indicating statistical significance of the difference.*

FDA Label Image

Structure-7.jpg (Structure 7)

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=51) shows about 19.6% of patients, while the Levetiracetam group (N=58) shows 43.1%, with a statistical significance marker denoting a significant difference versus placebo.*

FDA Label Image

Structure-8.jpg (Structure 8)

Bar chart comparing the percentage of patients responding to Placebo versus Levetiracetam treatment. The chart shows approximately 45.2% response for Placebo (N=84) and 72.2% for Levetiracetam (N=79), with an asterisk denoting statistical significance versus placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.